{
    "clinical_study": {
        "@rank": "28313", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra SC", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, single arm, long-term extension study will evaluate the safety\n      and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe\n      rheumatoid arthritis who have completed the 97-week WA22762 or the 96-week NA25220 core\n      study. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly (for patients\n      entering from WA22762) or every two weeks (for patients entering from NA25220) for 96 weeks,\n      with telephone call follow-up visits at Weeks 100 and 104."
        }, 
        "brief_title": "A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients who have completed the 97-week WA22762 or 96-week NA25220 core study on\n             subcutaneous or intravenous RoActemra/Actemra and based on the investigator's\n             judgment may continue to benefit from RoActemra/Actemra treatment in this study\n             investigating the subcutaneous formulation\n\n          -  Oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) up to the\n             maximum recommended dose are permitted if on a stable dose regimen for >/= 4 weeks\n             prior to baseline\n\n          -  Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed\n\n          -  Receiving treatment on an outpatient basis\n\n          -  Females of childbearing potential and males with female partners of childbearing\n             potential must agree to use reliable means of contraception\n\n        Exclusion Criteria:\n\n          -  Patients who have prematurely withdrawn from the WA22762 or NA25220 core studies for\n             any reason\n\n          -  Previous treatment with any cell-depleting therapies, including investigational\n             agents or approved therapies\n\n          -  History of severe allergic or anaphylactic reactions to human, humanized or mural\n             monoclonal antibodies\n\n          -  Evidence of serious uncontrolled concomitant disease\n\n          -  Current liver disease as determined by the principal investigator\n\n          -  History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic\n             ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other\n             symptomatic lower GI conditions that might predispose to perforations\n\n          -  Known active current or history of recurrent infections\n\n          -  Any major episode of infection requiring hospitalization or treatment with IV\n             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to\n             screening\n\n          -  Active TB requiring treatment within the previous 3 years\n\n          -  Primary or secondary immunodeficiency (history of or currently active)\n\n          -  Pregnant or breast feeding women\n\n          -  Body weight > 150 kg\n\n          -  Inadequate renal, hepatic or hematologic function\n\n          -  Positive for hepatitis B or hepatitis C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772316", 
            "org_study_id": "ML28488", 
            "secondary_id": "2012-002632-87"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra SC", 
            "description": "162 mg subcutaneously weekly or every two weeks, 96 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Merida", 
                        "country": "Spain", 
                        "state": "Badajoz", 
                        "zip": "06800"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santander", 
                        "country": "Spain", 
                        "state": "Cantabria", 
                        "zip": "39008"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Coruna", 
                        "country": "Spain", 
                        "state": "La Coru\u00f1a", 
                        "zip": "15006"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago De Compostela", 
                        "country": "Spain", 
                        "state": "La Coru\u00f1a", 
                        "zip": "15706"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Laguna", 
                        "country": "Spain", 
                        "state": "Tenerife", 
                        "zip": "38320"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valenica", 
                        "country": "Spain", 
                        "state": "Valencia", 
                        "zip": "46009"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barakaldo", 
                        "country": "Spain", 
                        "state": "Vizcaya", 
                        "zip": "48903"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bilbao", 
                        "country": "Spain", 
                        "state": "Vizcaya", 
                        "zip": "48013"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain", 
                        "zip": "29010"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41009"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "A MULTICENTER, OPEN-LABEL LONG-TERM EXTENSION STUDY OF WA22762 AND NA25220 TO EVALUATE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Long-term safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772316"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in disease activity: Disease Activity Score 28 - erythrocyte sedimentation rate (DAS28-ESR) and/or Simplified Disease Activity Index (SDAI)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 96"
            }, 
            {
                "measure": "Change in total tender joint count (TJC) / swollen joint count (SJC)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 96"
            }, 
            {
                "measure": "Proportion of patients with remission (DAS28 <2.6 or SDAI </=3.3) at Weeks 48 and 96", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Proportion of patients with DMARD/corticosteroid dose reductions and/or discontinuation", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Long-term patient compliance", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}